Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis - PubMed
a day ago
- #GLP-1 agonists
- #prediabetes
- #network meta-analysis
- Prediabetes is a transitional stage to type 2 diabetes, affecting ~1.12 billion people globally (2024).
- Anti-prediabetic drugs (e.g., metformin, SGLT2 inhibitors, GLP-1RAs, TZDs) significantly reduce HbA1c, FPG, weight, and BMI vs. placebo.
- Semaglutide (2.4 mg SC) showed optimal weight loss (-13.59 kg) and HbA1c reduction (-0.39%).
- Tirzepatide (15 mg) effectively lowered FPG (-9.58 mg/dL) and BMI.
- Pioglitazone (30 mg) excelled in lipid and FPG reduction.
- Safety: No significant difference in adverse events (AEs), but sitagliptin (100 mg) had higher serious AE risk.
- GLP-1RAs, GIP/GLP-1RAs, and TZDs balanced efficacy and safety; semaglutide and tirzepatide were top choices.
- Study design: Bayesian network meta-analysis of 55 RCTs (16,610 participants).